Unlike many pharmaceutical deals, which often deliver little, if any, value as anticipated new...

|By:, SA News Editor

Unlike many pharmaceutical deals, which often deliver little, if any, value as anticipated new treatments fail to materialize, Glaxo's (GSX) Stiefel acquisition looks likely to make money for shareholders. GSK -1.7%.